Studies have shown that when LAG3 antibody is used to treat tumor-bearing mice with colorectal cancer MC38 and fibrosarcoma Sa1N, tumor growth slightly decreases and the clearance rate is very limited. This evidence concerns the gene LAG3 and fibrosarcoma.